Early application of recombinant human IGF-1 (rhIGF-1) has been reported to prolong survival in patients with DS or RMS.[17] Continuous subcutaneous rhIGF-1 (mecasermin) infusion via an insulin pump improved glucose homeostasis in a patient with DS and appeared to be more effective than a single injection.[18] Because of its possible side effects and economic burden, mecasermin is still not approved and widely used; therefore, this drug should be used with full consideration of its therapeutic benefits. Here, INS is linked to Dravet syndrome.